FDA drug approvals 2016

Incremental clinical advances for Duchenne Muscular DystrophyJust last year, the FDA approved Exondys 51 (eteplirsen) for DMD, over the recommendations of FDA scientists and an external scientific advisory committee. Read more.
Why 2016 drug approvals fell
Why 2016 drug approvals fellWhile FDA approved far fewer new drugs in 2016 than 2015, the agency quickly approved novel and breakthrough therapies.